Amneal Pharmaceuticals launches oseltamivir phosphate for oral suspension, an AB-rated therapeutic equivalent for Tamiflu, in a 6 mg/mL strength. The powder-finished dosage form is made in the United States and packaged in bottles providing 60 mL of usable volume after constitution. Amneal’s oseltamivir phosphate for oral suspension joins its oral solid capsule form approved and launched in July 2017. The liquid dosage form is intended to help patients, particularly the elderly and young, who are unable to use an oral solid form.